戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ts specific and multivalent interaction with acid beta-glucosidase.
2  correlated with their activation effects on acid beta-glucosidase.
3 ficient activity of the lysosomal hydrolase, acid beta-glucosidase.
4 the cell from adverse hydrolytic activity of acid beta-glucosidase.
5                Loss-of-function mutations in acid beta-glucosidase 1 (GBA1) are among the strongest g
6 ough the salvage pathway involving, in part, acid beta-glucosidase 1 (GBA1), which cleaves glucosylce
7    In the present study, we examined whether acid beta-glucosidase 1 (GBA1), which hydrolyzes glucosy
8 isease resulting from a defect in the enzyme acid beta-glucosidase 1.
9 posin B and C localized the neurotrophic and acid beta-glucosidase activation properties to the carbo
10 CD-/- mice resulted in cellular decreases of acid beta-glucosidase activity and protein.
11 rase at dose of 5 U/kg bodyweight normalised acid beta-glucosidase activity of splenic Gaucher's cell
12 Biallelic mutations in GBA1 reduce lysosomal acid beta-glucosidase activity, and its substrates, gluc
13 rapid neurodegenerative course had two novel acid beta-glucosidase alleles: a complex, maternally der
14      Conduritol B epoxide is an inhibitor of acid beta-glucosidase, and lowers glucosylceramide degra
15          The x-ray structure of N370S mutant acid beta-glucosidase at acidic and neutral pH values in
16 saposin C binding and further enhancement of acid beta-glucosidase catalytic activity.
17    The finding of neutralizing antibodies to acid beta-glucosidase during enzyme therapy for Gaucher
18                          A loss in lysosomal acid-beta-glucosidase enzyme (GCase) activity due to bia
19 rder, results from the deficient activity of acid beta-glucosidase (GBA).
20                                The lysosomal acid beta-glucosidase GBA1 and the non-lysosomal beta-gl
21                      Isofagomine (IFG) is an acid beta-glucosidase (GCase) active site inhibitor that
22 (LSD), is caused by insufficient activity of acid beta-glucosidase (GCase) and the resultant glucosyl
23                      Inherited deficiency of acid beta-glucosidase (GCase) due to biallelic mutations
24       Gaucher disease is caused by defective acid beta-glucosidase (GCase) function.
25                          Defective lysosomal acid beta-glucosidase (GCase) in Gaucher disease causes
26 ll model (CBE-N2a) was created by inhibiting acid beta-glucosidase (GCase) in N2a cells with condurit
27                                              Acid beta-glucosidase (GCase) is a 497-amino acid, membr
28 inherited disease caused by mutations at the acid beta-glucosidase (GCase) locus (GBA).
29  lysosomal sphingolipid degradation pathway, acid beta-glucosidase (GCase) requires saposin C for opt
30 disease is caused by mutations in the enzyme acid beta-glucosidase (GCase), the most common of which
31 ease is caused by mutations in GBA1 encoding acid beta-glucosidase (GCase).
32 d glucosylceramide (GC) cleavage activity by acid beta-glucosidase (GCase).
33  GBA1 gene that encodes the lysosomal enzyme acid beta-glucosidase (GCase).
34                      Human lysosomal enzymes acid-beta-glucosidase (GCase) and acid-alpha-galactosida
35 utations leading to functional deficiency of acid-beta-glucosidase (GCase).
36 ptomatic patients with Gaucher disease (GD) (acid beta-glucosidase [Gcase] deficiency) are treated wi
37 ubtypes, all resulting from mutations in the acid beta-glucosidase gene.
38 rrelations and functional domains within the acid beta-glucosidase gene.
39 e disorder caused by deficiency in lysosomal acid beta-glucosidase (GlcCerase), the enzyme responsibl
40                                          The acid beta-glucosidase (glucocerbrosidase (GCase)) bindin
41 or for the hydrolysis of glucosylceramide by acid beta-glucosidase in mammals.
42 nactivated the wild-type, but not the N370S, acid beta-glucosidase in vitro.
43 l B epoxide, a potent inhibitor of lysosomal acid beta-glucosidase, inhibited pyridoxine-beta-D-gluco
44  CD spectral changes indicated saposin C and acid beta-glucosidase interaction only in the presence o
45                                              Acid beta-glucosidase is a lysosomal membrane protein th
46                   A conformational change of acid beta-glucosidase is shown to accompany activity rec
47 orage disease, is caused by mutations at the acid beta-glucosidase locus.
48 ally distinct subtypes result from different acid beta-glucosidase mutations encoding enzymes with ab
49                                Inhibition of acid beta-glucosidase promoted faster axonal elongation
50                      These studies show that acid beta-glucosidase requires interfaces composed of NC
51    Periodic infusions of macrophage-targeted acid beta-glucosidase reverse hepatosplenomegaly, hemato
52 therapy developed neutralizing antibodies to acid beta-glucosidase that were associated with a lack o
53 , carrying mutation(s) in GBA, which encodes acid beta-glucosidase, were recruited at the SZMC Gauche
54 d minor allergic reactions and antibodies to acid beta-glucosidase within the first 6 months of treat